➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Colorcon
Harvard Business School
Johnson and Johnson
Dow

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AT-527


Email this page to a colleague

« Back to Dashboard

Clinical Trials for AT-527

Trial ID Title Status Sponsor Phase Summary
NCT03219957 ↗ Study of AT-527 in Healthy and HCV-Infected Subjects Recruiting Atea Pharmaceuticals, Inc. Phase 1 This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In addition, the study will assess the antiviral activity of AT-527 in subjects infected with HCV.
NCT04019717 ↗ Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection Recruiting Atea Pharmaceuticals, Inc. Phase 2 The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.
NCT04309734 ↗ Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Recruiting Atea Pharmaceuticals, Inc. Phase 1/Phase 2 This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527 after 8 weeks of treatment in HCV-infected subjects.
NCT04396106 ↗ Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) Not yet recruiting Atea Pharmaceuticals, Inc. Phase 2 The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 10 days. Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy and safety observations will be compared for treatment with active AT-527 tablets + SOC vs. placebo tablets + SOC.
NCT04709835 ↗ Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 Not yet recruiting Atea Pharmaceuticals, Inc. Phase 2 This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized and are otherwise healthy.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for AT-527

Condition Name

Condition Name for
Intervention Trials
Healthy Volunteer Study 5
COVID-19 3
Hepatitis C, Chronic 3
Chronic Hepatitis C 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Hepatitis C, Chronic 3
Hepatitis C 3
Hepatitis A 3
Hepatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AT-527

Trials by Country

Trials by Country for
Location Trials
United States 8
Spain 7
Ukraine 6
Brazil 6
Mexico 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Nebraska 1
South Carolina 1
Ohio 1
Missouri 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AT-527

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 2 3
Phase 1/Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 7
Not yet recruiting 4
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AT-527

Sponsor Name

Sponsor Name for
Sponsor Trials
Atea Pharmaceuticals, Inc. 12
Hoffmann-La Roche 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Mallinckrodt
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.